News

News Archive

  • 05.18.2020  |  CARB-X funds Facile Therapeutics to develop a new treatment to prevent recurring C. difficile bacterial infections

    CARB-X is awarding Facile Therapeutics, based in Belmont, California, USA, up to $1.26 million to develop a new orally bioavailable drug to treat recurring infections caused by Clostridium difficile. Facile could receive up to $17 million more in additional funding from CARB-X if the project achieves certain development milestones, for a potential total of $18.26 million.

    Full Story

  • 05.11.2020  |  CARB-X funds 60th project – $220M invested so far, plus millions more if milestones are met

    CARB-X announced its 60th award today, representing more than $220 million invested since CARB-X was established in 2016 to support the early development of innovative products to fight drug resistance.

    Full Story

  • 05.11.2020  |  CARB-X awards Day Zero Diagnostics $6.2M to develop a new test that would diagnose deadly superbug infections faster and determine what antibiotic would be most effective

    CARB-X is awarding Day Zero Diagnostics, based in Boston, up to US$6.2 million in non-dilutive funding to develop a diagnostic system that could diagnose bacterial infections more quickly – within hours rather than days - and show physicians which antibiotics are most likely to effectively treat the infection. The innovative technology combines whole-genome sequencing and machine learning to identify the species of a pathogen and its drug-resistance profile without the need for culture, providing physicians with vital information to speed the appropriate treatment of serious drug-resistant bacterial infections in hours rather than days.

    Full Story

  • 03.17.2020  |  CARB-X funds Microbiotix to develop a novel oral antibiotic to treat multidrug-resistant gonorrhea

    CARB-X is awarding Microbiotix, a US-based clinical-stage biopharmaceutical company in Worcester, MA, up to US$2.86 million in non-dilutive funding to develop a new oral antibiotic to treat multidrug-resistant gonorrhea, a sexually transmitted disease caused by bacteria that have developed resistance to all but one existing antibiotic.  If the project successfully achieves certain development milestones, Microbiotix will be eligible for an additional $16 million in funding from CARB-X.

    Full Story

  • 02.25.2020  |  CARB-X funds Peptilogics to develop a new class of antibiotics to treat serious superbug infections associated with implants

    CARB-X is awarding Peptilogics, headquartered in Pittsburgh, USA, up to US$2.56 million in non-dilutive funding to develop a new class of peptide antibiotics with broad activity against drug-resistant bacteria.  The company could receive up to $9.61 million more in additional funding if the project achieves certain development milestones, for a potential total of up to $12.17 million.

    Full Story

  • 02.18.2020  |  CARB-X funds Lytica Therapeutics to develop antibacterial peptides to treat drug-resistant infections in the lungs and other parts of the body

    CARB-X is awarding Lytica Therapeutics, based in Cambridge, Massachusetts, USA, up to US$5.3 million in non-dilutive funding to develop antibacterial peptides with broad activity against multidrug-resistant bacteria.

    Full Story

  • 02.04.2020  |  CARB-X funds Pattern Bioscience to develop a new rapid diagnostic for drug-resistant bacterial infections

    CARB-X is awarding Pattern Bioscience (formerly operating as Klaris Diagnostics), based in Austin, Texas, US, up to US$6.8 million in non-dilutive funding to develop a rapid identification and antimicrobial susceptibility test (ID/AST) to diagnose drug resistant infections quickly, and provide health professionals with vital information about which pathogen is causing the infection and which antibiotic is most likely to cure the infection.

    Full Story

  • 01.13.2020  |  CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them

    CARB-X is awarding Trellis Bioscience, of Redwood City, California, USA, up to $3.2 million in non-dilutive funding, with the possibility of $3.8 million more if certain project milestones are met, to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics.

    Full Story

  • 01.08.2020  |  CARB-X funds TAXIS Pharmaceuticals to accelerate development of innovative efflux pump inhibitors (EPIs), a new drug class that would impair bacteria’s ability to fight antibiotics

    CARB-X is awarding TAXIS Pharmaceuticals of Monmouth Junction, New Jersey, USA, up to US$3.2 million in non-dilutive funding to develop efflux pump inhibitors (EPI), a new drug class designed to destroy a major mechanism of multi-drug-resistant Pseudomonas aeruginosa bacteria. TAXIS is eligible for additional funding of up to $11.4 million if the project achieves certain milestones. TAXIS’ EPIs are designed to disable the bacteria’s efflux pumps, which act like bilge pumps to flush out antibiotics from the bacterial cell in order to safeguard the superbug from the effects of antibiotics.

    Full Story

  • 01.07.2020  |  CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria

    CARB-X is awarding Centauri Therapeutics of Sandwich, UK, up to $1.4 million in non-dilutive funding to develop a novel dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens, including drug-resistant strains of Enterobacteriaceae, P. aeruginosa, and A.baumannii.

    Full Story